JP2020002172A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020002172A5 JP2020002172A5 JP2019167098A JP2019167098A JP2020002172A5 JP 2020002172 A5 JP2020002172 A5 JP 2020002172A5 JP 2019167098 A JP2019167098 A JP 2019167098A JP 2019167098 A JP2019167098 A JP 2019167098A JP 2020002172 A5 JP2020002172 A5 JP 2020002172A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- monoclonal antibody
- seq
- administered
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562232343P | 2015-09-24 | 2015-09-24 | |
| US62/232,343 | 2015-09-24 | ||
| US201662375825P | 2016-08-16 | 2016-08-16 | |
| US62/375,825 | 2016-08-16 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018515658A Division JP2018532728A (ja) | 2015-09-24 | 2016-09-23 | （持続性）外傷後頭痛の予防、治療および低減 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020002172A JP2020002172A (ja) | 2020-01-09 |
| JP2020002172A5 true JP2020002172A5 (https=) | 2020-09-10 |
Family
ID=57121460
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018515658A Pending JP2018532728A (ja) | 2015-09-24 | 2016-09-23 | （持続性）外傷後頭痛の予防、治療および低減 |
| JP2019167098A Pending JP2020002172A (ja) | 2015-09-24 | 2019-09-13 | （持続性）外傷後頭痛の予防、治療および低減 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018515658A Pending JP2018532728A (ja) | 2015-09-24 | 2016-09-23 | （持続性）外傷後頭痛の予防、治療および低減 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20170088612A1 (https=) |
| EP (1) | EP3353202B1 (https=) |
| JP (2) | JP2018532728A (https=) |
| KR (2) | KR20200035163A (https=) |
| CN (1) | CN108473560A (https=) |
| AU (2) | AU2016325738A1 (https=) |
| CA (1) | CA2999809A1 (https=) |
| EA (1) | EA201890578A1 (https=) |
| ES (1) | ES2846878T3 (https=) |
| HK (1) | HK1258385A1 (https=) |
| IL (1) | IL258008A (https=) |
| MX (1) | MX2018003713A (https=) |
| WO (1) | WO2017051385A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012258980B8 (en) | 2011-05-20 | 2017-06-15 | H. Lundbeck A/S | Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers |
| TWI685505B (zh) | 2011-05-20 | 2020-02-21 | 美商艾爾德生物控股有限責任公司 | 抗降血鈣素基因相關胜肽（ａｎｔｉ-ｃｇｒｐ）組成物及其用途 |
| US20170114122A1 (en) | 2015-10-23 | 2017-04-27 | Alderbio Holdings Llc | Regulation of glucose metabolism using anti-cgrp antibodies |
| JP6491669B2 (ja) | 2014-02-05 | 2019-03-27 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｃｇｒｐ活性化合物の錠剤製剤 |
| US12168004B2 (en) | 2014-02-05 | 2024-12-17 | Merck Sharp & Dohme Llc | Treatment of migraine |
| PE20161439A1 (es) | 2014-03-21 | 2017-01-26 | Teva Pharmaceuticals Int Gmbh | Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos |
| WO2018055574A1 (en) | 2016-09-23 | 2018-03-29 | Teva Pharmaceuticals International Gmbh | Treating refractory migraine |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| US12383545B1 (en) | 2018-06-08 | 2025-08-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| US10899826B1 (en) | 2018-09-13 | 2021-01-26 | Teva Pharmaceuticals International Gmbh | Pharmaceutical compositions for an anti-CGRP antagonist antibody |
| CN113227140A (zh) | 2019-01-08 | 2021-08-06 | H.隆德贝克有限公司 | 使用抗cgrp抗体急性治疗和快速治疗头痛 |
| AU2020259461A1 (en) * | 2019-04-18 | 2021-11-11 | Allergan Sales, Llc | CGRP antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo |
| KR20210124867A (ko) | 2020-04-06 | 2021-10-15 | 하. 룬드벡 아크티에셀스카브 | 항-cgrp 항체를 사용하는 편두통 관련 성가심 증상 (mbs) 의 치료 |
| CN116096399A (zh) * | 2020-06-03 | 2023-05-09 | 米奥托克斯有限责任公司 | 用于治疗偏头痛病症的区带性和靶向方法和用途 |
| CN116390712A (zh) | 2020-07-29 | 2023-07-04 | 阿勒根制药国际有限公司 | 治疗偏头痛 |
| CA3206184A1 (en) | 2020-12-22 | 2022-06-30 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| WO2023049920A1 (en) | 2021-09-27 | 2023-03-30 | Allergan Pharmaceuticals International Limited | Combination comprising atogepant for treating migraine |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9704770D0 (sv) * | 1997-12-19 | 1997-12-19 | Astra Ab | New use |
| MY153249A (en) * | 2005-11-14 | 2015-01-29 | Rinat Neuroscience Corp | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
| TWI685505B (zh) * | 2011-05-20 | 2020-02-21 | 美商艾爾德生物控股有限責任公司 | 抗降血鈣素基因相關胜肽（ａｎｔｉ-ｃｇｒｐ）組成物及其用途 |
| EP2802659A1 (en) * | 2012-01-10 | 2014-11-19 | Noxxon Pharma AG | Nucleic acids specifically binding cgrp |
| US8722060B2 (en) * | 2012-05-23 | 2014-05-13 | William J. Binder | Method of treating vertigo |
-
2016
- 2016-09-23 EA EA201890578A patent/EA201890578A1/ru unknown
- 2016-09-23 CA CA2999809A patent/CA2999809A1/en not_active Abandoned
- 2016-09-23 WO PCT/IB2016/055720 patent/WO2017051385A1/en not_active Ceased
- 2016-09-23 US US15/274,331 patent/US20170088612A1/en not_active Abandoned
- 2016-09-23 KR KR1020207008057A patent/KR20200035163A/ko not_active Withdrawn
- 2016-09-23 CN CN201680068514.8A patent/CN108473560A/zh active Pending
- 2016-09-23 JP JP2018515658A patent/JP2018532728A/ja active Pending
- 2016-09-23 MX MX2018003713A patent/MX2018003713A/es unknown
- 2016-09-23 AU AU2016325738A patent/AU2016325738A1/en not_active Abandoned
- 2016-09-23 EP EP16778888.4A patent/EP3353202B1/en active Active
- 2016-09-23 KR KR1020187011355A patent/KR20180058777A/ko not_active Ceased
- 2016-09-23 HK HK19100783.0A patent/HK1258385A1/zh unknown
- 2016-09-23 ES ES16778888T patent/ES2846878T3/es active Active
-
2018
- 2018-03-11 IL IL258008A patent/IL258008A/en unknown
-
2019
- 2019-06-11 US US16/437,776 patent/US20200148761A1/en not_active Abandoned
- 2019-09-13 JP JP2019167098A patent/JP2020002172A/ja active Pending
- 2019-11-06 AU AU2019261726A patent/AU2019261726A1/en not_active Abandoned
-
2021
- 2021-04-05 US US17/222,737 patent/US20220048986A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020002172A5 (https=) | ||
| JP2019530683A5 (https=) | ||
| Kolesnik et al. | Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication | |
| JP2008540447A5 (https=) | ||
| JP2020503260A5 (https=) | ||
| JP2014114288A5 (https=) | ||
| EP3201231B1 (en) | Methods of treating systemic lupus erythematosus using a domain antibody directed against cd28 | |
| JP2017510579A5 (https=) | ||
| TW201024315A (en) | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide | |
| KR20120100914A (ko) | 에프라투주맙을 이용한 자가면역 및 염증 질환의 치료 | |
| RU2019140933A (ru) | Средства, пути применения и способы лечения | |
| RU2017145662A (ru) | Моноклональные антитела и способы их применения | |
| JP2020527152A5 (https=) | ||
| JP2018529635A5 (https=) | ||
| RU2013157177A (ru) | Способы лечения системной красной волчанки, склеродермии и миозита | |
| JP2020515577A5 (https=) | ||
| IL292706A (en) | Type i interferon inhibition in systemic lupus erythematosus | |
| JP2021502065A5 (https=) | ||
| EP4426347A1 (en) | Composition for treatment and prevention of covid-19 | |
| JP2022500382A5 (https=) | ||
| US20250263472A1 (en) | Compositions and methods for treating and suppressing allergic responses | |
| EP4376885A1 (en) | Methods for treating acute myeloid leukemia with anti-ilt3 antibodies | |
| Rose et al. | Monoclonal antibody treatments for multiple sclerosis | |
| TW202508630A (zh) | 治療表現ｃｄ２０之ｂ細胞癌症之方法 | |
| JP2005529152A5 (https=) |